Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric

NCT07304271 is registered in ClinicalTrials.gov with Magnus Nilsson as lead sponsor.

NCT NCT07304271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07304271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric
Lead sponsor
Magnus Nilsson
Phase
Phase 3
Overall status
Recruiting
Start date
November 5, 2025
Completion date
January 31, 2031
Enrollment
262 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer peritoneal metastases